UBS has reaffirmed its 'buy' recommendation on Alcon, raising its target price from CHF 87 to CHF 92, a new target with 14% upside potential for the Swiss ophthalmology group's shares.

EPS growth in the mid-10% range is now being delivered consistently, while the outlook for catalysts over the next 12 to 18 months is rich", says the broker in the summary of its research note.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.